Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Gritstone bio, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT05456165
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Christ Hospital Cancer Center, Cincinnati, Ohio, United States
🇺🇸NYU Langone Health, New York, New York, United States
Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 3
- Registration Number
- NCT05448677
- Locations
- 🇫🇷
University Hospital, Grenoble, France
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Tvardi Therapeutics, Incorporated
- Target Recruit Count
- 166
- Registration Number
- NCT05440708
- Locations
- 🇺🇸
The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 874
- Registration Number
- NCT05425940
- Locations
- 🇺🇸
Exelixis Clinical Site #77, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #106, Philadelphia, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #103, Pittsburgh, Pennsylvania, United States
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 200
- Registration Number
- NCT05411081
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05394337
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT05359861
- Locations
- 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Sarah Cannon Research Institute - Tennessee Oncology, Nashville, Tennessee, United States
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 340
- Registration Number
- NCT05361395
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
- Conditions
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 77
- Registration Number
- NCT05333458
- Locations
- 🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT05315713
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪CHU UCL Namur - Mont-Godinne, Yvoir, Belgium
🇩🇪Universitaet Duisburg-Essen, Essen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.